<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The hyperfractionated <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> (hyper-CVAD) regimen has impressive efficacy in several <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> but is associated with considerable short-term haematological toxicity </plain></SENT>
<SENT sid="1" pm="."><plain>Secondary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) also occurs </plain></SENT>
<SENT sid="2" pm="."><plain>In this retrospective study, we also describe other prolonged haematological sequelae of this regimen </plain></SENT>
<SENT sid="3" pm="."><plain>One hundred and twenty-five patients were treated with a median of six hyper-CVAD cycles and followed for a median of 28 months </plain></SENT>
<SENT sid="4" pm="."><plain>Follow-up for cytopenias was censored at the next cytotoxic therapy </plain></SENT>
<SENT sid="5" pm="."><plain>At 3 months post-therapy, 77 patients were evaluable </plain></SENT>
<SENT sid="6" pm="."><plain>Cytopenias persisted in 59% of patients </plain></SENT>
<SENT sid="7" pm="."><plain>Requirement for dose attenuation was the only factor significantly associated with persisting cytopenias (p&lt;0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>The median time to normalisation of counts for those with post-treatment cytopenias in the respective lineages was 9 months (range, 6-12) for <z:hpo ids='HP_0001903'>anaemia</z:hpo>, 6 months (range, 6-30) for <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and 9 months (range, 6-30) for <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was diagnosed in four patients at 4, 21, 24 and 37 months after therapy with a cumulative incidence rate of 4.43% at 4 years </plain></SENT>
<SENT sid="10" pm="."><plain>These results indicate a considerable rate of prolonged haematological toxicity after hyper-CVAD and a modest rate of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> at this limited follow-up </plain></SENT>
<SENT sid="11" pm="."><plain>These findings likely reflect cumulative damage to haematopoietic stem cells </plain></SENT>
</text></document>